loading
Schlusskurs vom Vortag:
$56.19
Offen:
$56.19
24-Stunden-Volumen:
2.99M
Relative Volume:
1.51
Marktkapitalisierung:
$11.02B
Einnahmen:
$2.95B
Nettoeinkommen (Verlust:
$523.88M
KGV:
21.25
EPS:
2.69
Netto-Cashflow:
$620.18M
1W Leistung:
+5.60%
1M Leistung:
+0.21%
6M Leistung:
-14.02%
1J Leistung:
-30.47%
1-Tages-Spanne:
Value
$56.19
$57.61
1-Wochen-Bereich:
Value
$53.76
$57.61
52-Wochen-Spanne:
Value
$52.93
$94.85

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Name
Firmenname
Biomarin Pharmaceutical Inc
Name
Telefon
(415) 506-6700
Name
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Name
Mitarbeiter
3,040
Name
Twitter
Name
Nächster Verdiensttermin
2024-10-29
Name
Neueste SEC-Einreichungen
Name
BMRN's Discussions on Twitter

Vergleichen Sie BMRN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BMRN
Biomarin Pharmaceutical Inc
57.17 11.02B 2.95B 523.88M 620.18M 2.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-24 Hochstufung Oppenheimer Perform → Outperform
2024-11-15 Eingeleitet Wolfe Research Outperform
2024-10-30 Herabstufung William Blair Outperform → Mkt Perform
2024-10-10 Fortgesetzt Raymond James Outperform
2024-08-20 Hochstufung Bernstein Mkt Perform → Outperform
2024-05-17 Herabstufung Robert W. Baird Outperform → Neutral
2024-05-14 Eingeleitet Evercore ISI Outperform
2023-11-15 Eingeleitet Wells Fargo Overweight
2023-10-23 Hochstufung Bernstein Underperform → Mkt Perform
2023-09-28 Eingeleitet Raymond James Mkt Perform
2023-09-18 Eingeleitet UBS Buy
2023-07-27 Eingeleitet Scotiabank Sector Perform
2023-07-05 Hochstufung BMO Capital Markets Market Perform → Outperform
2023-06-14 Fortgesetzt Credit Suisse Outperform
2023-03-21 Eingeleitet Bernstein Underperform
2023-02-22 Herabstufung Oppenheimer Outperform → Perform
2023-02-21 Eingeleitet Citigroup Neutral
2023-01-30 Eingeleitet BMO Capital Markets Market Perform
2023-01-18 Eingeleitet Canaccord Genuity Hold
2022-10-31 Hochstufung Oppenheimer Perform → Outperform
2022-07-13 Eingeleitet Cantor Fitzgerald Overweight
2022-06-13 Fortgesetzt Wedbush Neutral
2022-04-25 Hochstufung Morgan Stanley Equal-Weight → Overweight
2021-11-22 Hochstufung William Blair Mkt Perform → Outperform
2021-10-07 Fortgesetzt Jefferies Buy
2021-09-09 Hochstufung Stifel Hold → Buy
2021-06-04 Fortgesetzt Robert W. Baird Outperform
2021-04-26 Fortgesetzt Credit Suisse Outperform
2021-03-04 Fortgesetzt Guggenheim Buy
2021-03-01 Hochstufung Evercore ISI In-line → Outperform
2020-08-20 Herabstufung Citigroup Buy → Neutral
2020-08-20 Herabstufung William Blair Outperform → Mkt Perform
2020-08-19 Herabstufung Evercore ISI Outperform → In-line
2020-08-19 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2020-08-19 Herabstufung Stifel Buy → Hold
2020-07-08 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-07-06 Bestätigt Citigroup Buy
2020-01-28 Eingeleitet BMO Capital Markets Market Perform
2020-01-27 Eingeleitet BMO Capital Markets Market Perform
2020-01-24 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2019-11-27 Hochstufung Barclays Equal Weight → Overweight
2019-11-12 Eingeleitet SunTrust Buy
2019-10-17 Fortgesetzt BofA/Merrill Buy
2019-05-23 Fortgesetzt Citigroup Buy
2019-04-09 Fortgesetzt Raymond James Outperform
2019-01-02 Herabstufung Raymond James Outperform → Mkt Perform
2018-12-14 Eingeleitet Wolfe Research Outperform
2018-10-01 Eingeleitet Cantor Fitzgerald Overweight
2018-08-07 Bestätigt Stifel Buy
2018-08-03 Bestätigt Stifel Buy
Alle ansehen

Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten

pulisher
Jun 18, 2025

BioMarin Generates Patient Experience Data With Early And Often Engagement - Clinical Leader

Jun 18, 2025
pulisher
Jun 15, 2025

Jim Cramer on BioMarin: “I Don’t Think It Works Now” - MSN

Jun 15, 2025
pulisher
Jun 14, 2025

BioMarin’s SWOT analysis: stock growth potential amid rare disease focus - Investing.com

Jun 14, 2025
pulisher
Jun 13, 2025

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - MSN

Jun 13, 2025
pulisher
Jun 12, 2025

Jim Cramer Discussed These 16 Stocks Recently - Insider Monkey

Jun 12, 2025
pulisher
Jun 12, 2025

Phenylktonuria Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Erytech Pharma SA, Homology Medicines Inc., Synlogic Inc., BioMarin Pharmaceuticals - Barchart.com

Jun 12, 2025
pulisher
Jun 12, 2025

Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs - Benzinga

Jun 12, 2025
pulisher
Jun 09, 2025

Morquio Syndrome (MPS-IV) Drug Market Is Booming So Rapidly - openPR.com

Jun 09, 2025
pulisher
Jun 05, 2025

Here Are All 6 Stocks I've Bought Through 5 Months of 2025 - The Motley Fool

Jun 05, 2025
pulisher
Jun 05, 2025

The Top 12 Companies Hiring in Biopharma Now - BioSpace

Jun 05, 2025
pulisher
Jun 04, 2025

Marin Awareness Walk Draws Over 100 Community Members - Patch

Jun 04, 2025
pulisher
Jun 02, 2025

inozyme pharma announces executive bonuses amid merger plans By Investing.com - Investing.com Nigeria

Jun 02, 2025
pulisher
Jun 02, 2025

inozyme pharma announces executive bonuses amid merger plans - Investing.com

Jun 02, 2025
pulisher
May 30, 2025

BioMarin Now Targets $3 Bln Revenue Goal For 2025 - RTTNews

May 30, 2025
pulisher
May 30, 2025

The past five years for BioMarin Pharmaceutical (NASDAQ:BMRN) investors has not been profitable - simplywall.st

May 30, 2025
pulisher
May 29, 2025

Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock? - MSN

May 29, 2025
pulisher
May 28, 2025

Is The Options Market Predicting A Spike In BioMarin Pharmaceutical Stock? - Barchart.com

May 28, 2025
pulisher
May 28, 2025

Noonan Syndrome Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Novo Nordisk A/S, BioMarin Pharma - The Globe and Mail

May 28, 2025
pulisher
May 27, 2025

FDA issues BioMarin complete response letter for Duchenne muscular dystrophy drug Kyndrisa - FirstWord Pharma

May 27, 2025
pulisher
May 27, 2025

Stifel maintains Buy on BioMarin, price target at $91 By Investing.com - Investing.com India

May 27, 2025
pulisher
May 27, 2025

Stifel maintains Buy on BioMarin, price target at $91 - Investing.com

May 27, 2025
pulisher
May 26, 2025

Phenylktonuria Treatment Market Overall Study Report - openPR.com

May 26, 2025
pulisher
May 26, 2025

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance

May 26, 2025
pulisher
May 25, 2025

BioMarin’s SWOT analysis: genetic medicine firm’s stock shows growth potential - Investing.com

May 25, 2025
pulisher
May 24, 2025

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More - MSN

May 24, 2025
pulisher
May 24, 2025

Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens - MSN

May 24, 2025
pulisher
May 23, 2025

Rx Rundown: BioMarin, Novavax, CellCentric and more - Medical Marketing and Media

May 23, 2025
pulisher
May 22, 2025

BioMarin Pharmaceutical Approves Equity Plan Amendment - TipRanks

May 22, 2025
pulisher
May 22, 2025

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio - Yahoo

May 22, 2025
pulisher
May 22, 2025

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), ACADIA Pharmaceuticals (ACAD) and Quanterix (QTRX) - The Globe and Mail

May 22, 2025
pulisher
May 21, 2025

BioMarin’s Acquisition of Inozyme Pharma - Global Legal Chronicle

May 21, 2025
pulisher
May 21, 2025

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc.INZY - Business Wire

May 21, 2025
pulisher
May 21, 2025

6,941 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Acquired by Focus Partners Wealth - Defense World

May 21, 2025
pulisher
May 21, 2025

BioMarin agrees to acquire Inozyme for $270m - MSN

May 21, 2025
pulisher
May 20, 2025

Insider Sell Alert: Erin Burkhart Sells Shares of Biomarin Pharmaceutical Inc (BMRN) - GuruFocus

May 20, 2025
pulisher
May 19, 2025

Is this European biotech’s moment? — a BioCentury podcast - biocentury.com

May 19, 2025
pulisher
May 19, 2025

BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition - MSN

May 19, 2025
pulisher
May 19, 2025

BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal - MSN

May 19, 2025
pulisher
May 19, 2025

Inozyme Pharma finds buyer in BioMarin after strategic review - The Business Journals

May 19, 2025
pulisher
May 19, 2025

Bernstein raises BioMarin stock target to $95, maintains Outperform - Investing.com Australia

May 19, 2025
pulisher
May 19, 2025

Bernstein raises BioMarin stock target to $95, maintains Outperform By Investing.com - Investing.com Nigeria

May 19, 2025
pulisher
May 19, 2025

BioMarin: Inozyme Acquisition Falls Short Of Offsetting Looming Revenue Risks (Downgrade) - Seeking Alpha

May 19, 2025
pulisher
May 19, 2025

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

May 19, 2025
pulisher
May 18, 2025

BioMarin Buying Inozyme Pharma In $270 Million Deal - Pulse 2.0

May 18, 2025
pulisher
May 18, 2025

StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&A - Genetic Engineering and Biotechnology News

May 18, 2025

Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):